EC Pulmonology and Respiratory Medicine

In recent years, severe forms of acute pneumonia (AP) have emerged as a distinct group of diseases due to low treatment efficacy, frequent complications, and high mortality. However, amid the apparent rise in viral pneumonias, which, according to some data, already outnumber bacterial pneumonias, attempts to address this problem continue to stubbornly rely on the leading and decisive role of antibiotics. This article, drawing on the author's unique experience and accumulated material on this topic, critically analyzes existing misconceptions about the nature of AP and proposes ways to overcome the main obstacles to solving this problem.

 Keywords: Acute Pneumonia; Antibiotics; Side Effects; Etiology; Pathogenesis; Disease Concept

1. Podolsky SH. “The changing fate of pneumonia as a public health concern in 20^th-century America and beyond”. American Journal of Public Health 12 (2005): 2144-2154.
2. Abraham EP and Chain E. “An enzyme from bacteria able to destroy penicillin, 1940”. Reviews of Infectious Diseases 4 (1988): 677-678.
3. Rammelkamp T. “Resistance of Staphylococcus aureus to the action of penicillin”. Experimental Biology and Medicine 3 (1942): 386-389.
4. Avery OT., et al. “Acute lobar pneumonia: prevention and serum treatment”. Monographs of the Rockefeller Institute for Medical Research. Rockefeller Institute for Medical Research, New York (1917).
5. Cole RI. “Acute pulmonary infections”. De La Mar Lectures. Williams & Wilkins, Baltimore (1927-1928).
6. Sutliff WD and Finland M. “The significance of the newly classified types of pneumococci in disease: types IV to XX inclusive”. Journal of the American Medical Association 17 (1933): 1289-1295.
7. Heffron R. “Pneumonia, with special reference to pneumococcus lobar pneumonia”. Cambridge: Harvard University Press (1939).
8. Small JT. “A short history of the pneumococcus with special reference to lobar pneumonia”. Edinburgh Medical Journal 3 (1948): 129-141.
9. Klepikov I. “Acute pneumonia and its purulent and destructive complications in children in the midst of a major industrial centre of Western Siberia”. Dissertation for the degree of Doctor of Medical Science. Leningrad, USSR (1989).
10. Aminov RI. “A brief history of the antibiotic era: lessons learned and challenges for the future". Frontiers in Microbiology 1 (2010): 134.
11. Fleming A. "The Nobel Prize in Physiology or Medicine 1945 - Penicillin: Nobel Lecture". NobelPrize.org. (1945).
12. "MRSA History Timeline: The First Half-Century, 1959-2009". The University of Chicago Medical Center (2010).
13. “Global antimicrobial resistance and use surveillance system (‎GLASS)‎ report: 2022” (2022).
14. “Antimicrobial resistance” (2021).
15. Gadsby NJ and Musher DM. “The microbial etiology of community-acquired pneumonia in adults: from classical bacteriology to host transcriptional signatures”. Clinical Microbiology Reviews 4 (2022): e00015-22.
16. Shoar S and Musher DM. “Etiology of community-acquired pneumonia in adults: a systematic review”. Pneumonia 12 (2020): 11.
17. Carlos P., et al. “CURB-65 and long-term mortality of community-acquired pneumonia: a retrospective study on hospitalized patients”. Cureus 3 (2023): e36052.
18. Palomeque A., et al. “A review of the value of point-of-care testing for community-acquired pneumonia”. Expert Review of Molecular Diagnostics8 (2024): 729-742.
19. Metlay JP., et al. “Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America”. American Journal of Respiratory and Critical Care Medicine 7 (2019): e45-e67.
20. Martin-Loeches I., et al. “ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia”. Intensive Care Medicine 6 (2023): 615-632.
21. Huttner BD., et al. “COVID-19: don't neglect antimicrobial stewardship principles!”. Clinical Microbiology and Infection 7 (2020): 808-810.
22. Beović B., et al. “Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy 11 (2020): 3386-3390.
23. Rawson TM., et al. “Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support covid-19 antimicrobial prescribing”. Clinical Infectious Diseases 9 (2020): 2459-2468.
24. LO Gostin and GK Gronvall. “The origins of covid-19 - why it matters (and why it doesn’t)”. New England Journal of Medicine 25 (2023): 2305-2308.
25. Monto AS. "Coronaviruses". In Evans AS (ed.) Viral Infections of Humans: Epidemiology and Control. Springer US (1984): 151-165.
26. Visseaux B., et al. “Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016”. PLoS One7 (2017): e0180888.
27. Shah MM., et al. “Seasonality of common human coronaviruses, United States, 2014-2021”. Emerging Infectious Diseases 10 (2022): 1970-1976.
28. Oran DP and Topol EJ. “Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review”. Annals of Internal Medicine 5 (2020): 362-367.
29. Wu Z and McGoogan JM. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention”. Journal of the American Medical Association 13 (2020): 1239-1242.
30. Murad M and Martin JC. “Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages”. Nature Reviews Immunology 6 (2020): 355-362.
31. Zhou B., et al. “COVID‐19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations”. Journal of Medical Virology 5 (2021): 2694-2704.
32. Rabin EE., et al. “Clinical significance of culture-negative, PCR-positive bronchoalveolar lavage results in severe pneumonia”. ERJ Open Research 6 (2023): 00343-2023.
33. Pickens CI., et al. “Microbiology of severe community-acquired pneumonia and the role of rapid molecular techniques”. Seminars in Respiratory and Critical Care Medicine2 (2024): 158-168.
34. Maricar Malinis., et al. “Community-acquired pneumonia: a US perspective on the guideline gap”. Journal of Antimicrobial Chemotherapy5 (2024): 959-961.
35. “Myths, legends and real facts about acute lung inflammation”. Cambridge Scholars Publishing. Pages: 334. ISBN: 1-0364-0293-2 ISBN13: 978-1-0364-0293-8 (2024).
36. Sakamoto Y., et al. “In-hospital mortality associated with community-acquired pneumonia due to methicillin-resistant Staphylococcus aureus: a matched-pair cohort study”. BMC Pulmonary Medicine 1 (2021): 345.
37. Ding H., et al. “Incidence of drug-resistant pathogens in community-acquired pneumonia at a safety net hospital”. Microbiology Spectrum 8 (2024): e00792-24.
38. Albrich WC and Harbarth S. “Health-care workers: Source, vector, or victim of MRSA?” Lancet Infectious Diseases 5 (2008): 289-301.
39. Aubry-Damon H., et al. “Antimicrobial resistance in commensal flora of pig farmers”. Emerging Infectious Diseases 5 (2004): 873-879.
40. Graveland H., et al. “Methicillin resistant Staphylococcus aureus ST398 in veal calf farming: Human MRSA carriage related with animal antimicrobial usage and farm hygiene”. PLoS ONE6 (2010): e10990.
41. C Liu and M Holubar. “Should a MRSA nasal swab guide empiric antibiotic treatment?” NEJM Evidence 12 (2022): EVIDccon2200124.
42. Serwecińska Liliana. "Antimicrobials and antibiotic-resistant bacteria: a risk to the environment and to public health". Water 12 (2020): 3313.
43. World Health Organization. “Antimicrobial resistance” (2023).
44. Madhavi Thara. “Antibiotic Stewardship”. Medicon Medical Sciences3 (2024): 01-02.
45. Colledge NR., et al. “Davidson's Principles and Practice of Medicine (21^st edition)”. Edinburgh: Churchill Livingstone/Elsevier. ISBN 978-0-7020-3084-0 (2010).
46. "Normal Hemodynamic Parameters - Adult". Edwards Lifesciences LLC (2010).
47. Schwiegk H. “Der Lungenentlastungsreflex”. Pflügers Archiv 236 (1935): 206-219.
48. Olivia Vynn. “Cardiology secrets”. Chapter 41. Adair Edition: 2, illustrated Published by Elsevier Health Sciences, 2001 ISBN 1-56053-420-6, 978-1-56053-420- (2001): 210.
49. M Stein and SE Levy. “Reflex and humoral responses to pulmonary embolism”. Progress in Cardiovascular Diseases3 (1974): 167-174.
50. Mohanty PK., et al. “Reflex effects of prolonged cardiopulmonary baroreceptor unloading in humans”. American Journal of Physiology 2 (1988): R320-R324.
51. Fu Q., et al. “Evidence for unloading arterial baroreceptors during low levels of lower body negative pressure in humans”. American Journal of Physiology-Heart and Circulatory Physiology 2 (2008): H480-H488.
52. Busch S., et al. “Evidence for a physiological role of pulmonary arterial baroreceptors in sympathetic neural activation in healthy humans”. Journal of Physiology5 (2020): 955-965.
53. Singer M., et al. “The third international consensus definitions for sepsis and septic shock (Sepsis-3)”. Journal of the American Medical Association8 (2016): 801-810.
54. Self WH., et al. “Liberal versus restrictive intravenous fluid therapy for early septic shock: rationale for a randomized trial”. Annals of Emergency Medicine 4 (2018): 457-466.
55. Shapiro NI., et al. “Early restrictive or liberal fluid management for sepsis-induced hypotension”. New England Journal of Medicine 6 (2023): 499-510.